Correlation of KIT and PDGFRA mutation status with sunitinib activity in imatinib-resistant GIST
Michael C. Heinrich(VA Portland Health Care System), George D. Demetri(Dana-Farber Cancer Institute), Charles M. Baum(Brigham and Women's Hospital), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Xin Huang(Lineage Cell Therapeutics (United States)), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Christopher L. Corless(Oregon Health & Science University), Jonathan A. Fletcher(Harvard University), Christopher D.�M. Fletcher(Brigham and Women's Hospital)
Unknown
October 1, 2006
Cited by 0
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k